Abstract
Objective -In many industrialised countries, health care third party payers are moving towards contracted provision arrangements with suppliers of hospital care. Essential to such a process is a standard approach to quantifying the care provided. This paper aims to outline the possible approaches to hospital product definition for the UK National Health Service, and recommends appropriate further research. Methods -All published and unpublished studies on hospital output measurement in the NHS since 1980 were sought for the purposes of the review. This included both discursive and empirical work, and no exclusion criteria were applied. Most empirical reports on this topic, however, come from the United States. Consequently, the published reports since 1980 from the USA, accessed from the Medline and Healthplan CD-ROM databases, have also been included in the overview. Conclusions -Where data are sufficient, the true casemix approach offers advantages over other methods of output measurement. In the UK NHS, two systems -diagnosis-related groups (DRGs) and healthcare resource groups (HRGs) -are the only casemix measures that have achieved any significant degree of attention. DRGs have been extensively evaluated internationally, and explain variations in resource use in the UK slightly better than do HRGs. As a local product, HRGs can be more easily adapted to the specific needs of the NHS internal market, however, and will thus probably emerge as a better measure for the UK in the long term. In both cases, locally de Product definition for healthcare contract distributed. The NHS Management Executive has responded by setting up the National Casemix Office (NCMO) and the National Steering Group on Costing (NSGC), with the aims of designing a uniform product definition system, and costing those products in a standardised way. 46 Data collection systems already in place in the UK are sufficient for most of the information needs of adequate hospital output measurement, and the NHS seems to be currently well placed to adapt local and international experience to suit the needs of the internal market. This paper aims to review the suitability of existing systems of product definition for use in the UK internal market. It is also hoped that this paper will assist researchers and policy makers elsewhere in the world in adapting what are largely North American systems to their own conditions. Approaches to hospital product definition Few would oppose the view that the principle purpose of hospitals is to bring about a change in health status of individual patients admitted to the institution, and hence also of the communities from which they come. There are other less well described hospital products also worthy of mention, such as the outpatient health gains, teaching and research, and amenity consumption goods such as hotel services. This paper will discuss the measurement of inpatient and outpatient health products only.
The inpatient health product Measuring actual changes in health status, or health related quality of life, must remain the gold standard for hospital product quantification. For the foreseeable future, however, data gathering constraints will prevent use of such methods, and hospital output quantification will imply using a variety of process or proxy measures. It is essentially in the choice of which of these process measures to combine that hospital product definition systems differ. Hornbrook7 provides a useful conceptual background to the measurement of hospital output. He divides the hospital product into three facets -volume, "casemix", and quality.
The volume aspect is easiest to measure, although fairly controversial in the NHS, where the "finished consultant episode" measure is particularly difficult to use for contracting purposes, as any number of episodes can be recorded during one hospital admission. Fuller discussions of this issue are given elsewhere.89 Quality issues have also attracted increased attention recently, with a spate of conferences and the launch of a UK journal devoted to the topic. Interpretations of the term still range widely, however, from the consumerist, all-encompassing "total quality management" approach, to circumscribed measures of medical outcome in particular diseases. This paper will concentrate on what Hornbrook has broadly described as "casemix" -that is, the disease features, and con- Like facility mix measures, service mix classification systems are concerned with the treatment process, from which is inferred a change in the health status. They do have significance at the individual patient level, and are derived from actual activity rather than potential for activity. Some measures, such as the Resource Based Relative Value Scale (RBRVS) system for estimating physician contribution to hospital product, are highly specific and correlate well with resource input."' 5 They are complicated to derive, however, and incorporate components that are highly value-laden, for example physician skill and stress associated with certain procedures. Others, such as the British United Provident Association (BUPA) schedule'6 used in the UK are far cruder, and are based principally on time taken to perform procedures.
The service mix approach is most useful for measuring short term technical efficiency of hospitals and is consequently of appeal primarily to hospital managers. Clearly, however, any amount of services rendered to a patient will only bring about a health improvement if they are appropriate for their particular diagnosis, age, sex, etc. Furthermore, there are usually diminishing returns for each increment in amount of services provided, implying the existence of an optimal level of treatment for every patient, above which overall efficiency would be impaired. If physicians or hospitals are reimbursed on the basis of the service mix that they provide to their patients, inappropriate interventions may be encouraged. Empirical evidence for this phenomenon is suggested by work on supplier induced demand in health care generally,'7 18 and illustrated, for example,
by the high procedure rates in some service mix based reimbursement systems.'920
If contracts are to reflect output at the individual patient level, service mix measures do provide one of the options available to providers and purchasers. Procedural data in the form of the Office of Population Censuses and Surveys (OPCS)-4 codes are available for all inpatient episodes in the UK, but data on most diagnostic and medical therapeutic activity are not. A more detailed coding system, Read codes,2122 would be able to support a higher degree of service mix specification, but are not widely used by hospitals. Supply side measurement, however, will always run the danger of implicitly assuming that the application of health technology is universally beneficial, and health care purchasers have been justifiably wary of reimbursing providers on this basis. 40 is a casemix system developed in the United States which aims to incorporate to a greater degree than DRGs the severity of a given disease in the classification system. It organises patients into approximately 400 diagnostic categories which are then stratified into ordinal severity stages. Disease Staging, in its routine data derivable form, measures primarily the number and type of secondary diagnosis codes, and hence is really more of a diagnostic complexity than a true severity score. Nevertheless, its ability to predict adverse outcomes is better than that of DRGs, suggesting that diagnostic complexity is a reasonable proxy for severity. Studies from the United States have indicated that Disease Staging is useful for comparing casemix differences between institutions, independently of the actual resources utilised in the treatment of patients.4' That is to say, while at a purely statistical level it is not as good a predictor of resource use as DRGs are, it does not confound treatment intensity with diagnostic casemix measurement, and therefore arguably acts as purer indicator of "need for care". This feature has led to suggestions that it may be most appropriate for use by purchasers.42 The information needed to derive Disease Staging categories can be obtained from routine NHS data, with approximately 95% of records being assigned to a Disease Staging category. Between 2 and 8% of records from different regions were assigned to non-specific groups, and it is a reasonably good predictor of both length of stay and mortality.42 It may be less useful than has been the case in the US, however, because of relatively lower levels of coding of secondary diagnoses in the UK. Some adaptation of US weights, possibly using local length of stay data and limited existing cost data from resource management sites, might be a useful stopgap until sufficient local cost data is collected.
Conclusions
Within the NHS internal market, there is some urgency in applying a uniform system for defining the hospital product if it is to function as a market at all. Even if the "market" approach to distributing health care funds, was dispensed with, however, there are still many benefits to be gained from having a system to measure hospital output. Clearly, what is immediately feasible, and what is optimal, are two very different entities. Possible short and long term approaches for the NHS are suggested.
In the short term, purchasers and providers need to be encouraged, possibly by means of the offer of centrally funded support staff, to experiment with using HRGs instead of specialty groupings in contracts. Some form of indicative cost weights, possibly in the form of a US/UK hybrid would need to be distributed to facilitate this exercise. Early use of casemix methods is also likely to spur improvements in data coding, which will in turn increase acceptance of the results generated by the casemix approach.
In the long term, assuming the continuation of the internal market in its current form, a strong case needs to be made for a universally applied prospectively determined payment system based on diagnostic casemix categories Improvement of the resource use and length of stay validity of HRGs should be a continuing process. One possible approach would be to collapse down similar categories in the existing system, with subsequent subdivision on the basis of factors other than medical diagnosis, for example dependency or age. Lastly, the production of up to date, good quality cost data will greatly encourage universal utilisation.
The success of any product definition drive within the NHS is likely to be sensitive to a number of exogenous factors as well. These include the availability of skilled and empowered management, both as purchasers and providers, and a more consistent and considered approach from the NHS Management Executive. Department of Health directives since 1991 have contained a myriad of conflicting instructions simultaneously freeing and overregulating the health care market. This policy of one step forward and one back does little to encourage creative thinking on the part of those working in the service. All this has led to a market which is, in most cases, not a market at all, except in respect of its burgeoning transaction costs. While product definition is arguably a necessity under any system that emerges, confusion as to the future health service structure discourages essential long term thinking about measuring NHS hospital output.
A number of generic conclusions with regard to product definition in industrialised countries may also be drawn from the experience in the UK and elsewhere. Output classifi- 
